Kaitlyn Bader, Associate Editor

Two dermatologists discuss how immune checkpoint inhibitors will change the way dermatologists manage skin cancer.

This week's edition of the Mainstream Patient features stories about recommended acne solutions from dermatologists, Latinx-owned beauty brands, the latest skin care trend of "skin energy," and more.

Click to see a preview of what to expect this week.

ICYMI, this week we had stories about new study data on roflumilast foam for scalp and body psoriasis, dupilumab's FDA approval, the future of basal cell carcinoma treatment, and more.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are trending for the month of September.

Pulse Biosciences' new technology will treat sebaceous hyperplasia patients with Fitzpatrick skin types I-III.

Arcutis Biotherapeutics announced positive results from the ARRECTOR phase 3 trial.

This week's edition of the Mainstream Patient features stories about the best sunscreens for fall, Botox for excessive sweating, Brad Pitt's entrance into the skin care industry, and more.

ICYMI, this week we had stories about the role of precision medicine for managing melanoma, a debridement drug for severe pediatric burns, roflumilast cream phase 3 results, and an exclusive KOL interview.

Roflumilast cream adds a much-needed element of simplicity for psoriasis patients and their dermatologists.

Arcutis Biotherapeutics’ roflumilast cream showed higher efficacy compared to vehicle in two phase 3 studies.

MediWound’s debridement drug will provide a safer non-surgical alternative to severe thermal burns for pediatric patients.

This week's edition of the Mainstream Patient features stories about skin cycling, skin care routines from dermatologists, upcoming nail trends, body care, and more.

ICYMI, this week we had stories about products to help manage acne, a case study on pediatric vitiligo, data results from a hidradenitis suppurativa clinical trial, BCC management, and more.

Bristol Myers Squibb’s nivolumab shows potential for treatment in earlier stages of melanoma.

SUNSHINE and SUNRISE trials showed superior efficacy over the placebo.

This week's edition of the Mainstream Patient features stories about the best retinol creams, the Blue Beauty movement, lip blushing, and more.

Taking a deep dive into alopecia areata allows for a better understanding of the cells that are responsible for disease development.

Deucravacitinib offers new hope for those with moderate-to-severe plaque psoriasis.

Study data was presented at EADV 2022 regarding socioeconomic status related to HS.

Joshua Zeichner, MD, and Mona Gohara, MD, discuss adherence issues and adverse effects related to topical treatments for acne vulgaris.

TMB-001 showed positive results in the reduction of congenital ichthyosis severity in a phase 2b CONTROL study.

DaxibotulinumtoxinA for Injection will provide long-lasting results with fewer injection treatments over time.

The relationship between mental health and psoriasis was discussed at EADV Congress 2022 in Milan, Italy.

This week's edition of the Mainstream Patient features stories about facial exfoliators, skin-picking disorders, hydra-facials, and more.

ICYMI, this week we had stories about non-prescription acne treatments, clinical study results, pediatric atopic dermatitis, and the EADV 2022 Congress.

Boehringer Ingelheim’s first treatment option for adults will help manage burdensome flares.

Revelle Aesthetics’ cellulite reduction device helps address frustrating aesthetic concerns.

AnaptysBio will refocus R&D efforts on its immune cell modulator pipeline.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are trending for the month of August.